Why did patients with cardiovascular disease in the Netherlands accept Q fever vaccination?

Vaccine

Volumn 30, Issue 23, 2012, Pages 3369-3375

  Bults, Marloes ^a,d   Beaujean, Desirée J M A ^b   Wijkmans, Clementine J ^c   Timen, Aura ^b   Richardus, Jan Hendrik ^a,d   Voeten, Hélène A C M ^a,d  

^a Public Health Service of the Rotterdam Region   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Municipal Public Health Service Hart voor Brabant   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Feelings of doubt; Information seeking behavior; Major motives; Q fever vaccination; Risk perception; Social influence; Vaccination acceptance

Indexed keywords

Q FEVER VACCINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; FEMALE; GENERAL PRACTITIONER; GOVERNMENT; HUMAN; INFECTION RISK; INFORMATION SEEKING; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT ATTITUDE; PATIENT DECISION MAKING; PERCEPTION; PRIORITY JOURNAL; Q FEVER; SOCIAL BEHAVIOR; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL VACCINES; CARDIOVASCULAR DISEASES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; NETHERLANDS; PATIENT ACCEPTANCE OF HEALTH CARE; Q FEVER; VACCINATION;

EID: 84859826703     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.056     Document Type: Article

References (37)

1. Parker N.R., Barralet J.H., Bell A.M. Q fever. Lancet 2006, 367:679-688.
2. Raoult D., Marrie T.J., Mege J.L. Natural history and pathophysiology of Q fever. Lancet Infect Dis 2005, 5:219-226.
3. Maurin M., Raoult D. Q fever. Clin Microbiol Rev 1999, 12:518-553.
4. Fenollar F., Fournier P.E., Carrieri M.P., Habib G., Messana T., Raoult D. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis 2001, 33:312-316.
5. Raoult D., Marrie T. Q fever. Clin Infect Dis 1995, 20:489-495.
6. Tissot Dupont H., Raoult D., Brouqui P., Janbon F., Peyramond D., Weiller P.J., et al. Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. Am J Med 1992, 93:427-434.
7. Karagiannis I., Morroy G., Rietveld A., Horrevorts A.M., Hamans M., Francken P., et al. Q fever outbreak in the Netherlands: a preliminary report. Eurosurveill 2007, 12(32):pii=3247.
8. van der Hoek W., Dijkstra F., Schimmer B., Schneeberger P.M., Vellema P., Wijkmans C. Q fever in the Netherlands: an update on the epidemiology and control measures. Eurosurveill 2010, 15(12):pii=19520.
9. Schimmer B., Morroy G., Dijkstra F., Schneeberger P.M., Weers-Pothoff G., Timen A., et al. Large ongoing Q fever outbreak in the south of the Netherlands, 2008. Eurosurveill 2008, 13(31):pii=18939.
10. Ministry of Health and Welfare. National Institute of Public Health and the Environment; 29 June 2011. Available from: . http://www.rivm.nl/Onderwerpen/Ziekten_Aandoeningen/Q/Q_koorts.
11. Schimmer B., ter Schegget R., Wegdam M., Zuchner L., de Bruin A., Schneeberger P.M., et al. The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. BMC Infect Dis 2010, 10:69.
12. Health Council of the Netherlands Human Vaccination Against Q Fever 2010, Health Council of the Netherlands, The Hague, Publication no. 2010/08.
13. CSL Biotherapies. Q-VAX Q fever vaccine and Q-VAX skin test. Product Information - TGA approved; 2008. Australia.
14. Ackland J.R., Worswick D.A., Marmion B.P. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-VAX (CSL) 1985-1990. Med J Austr 1994, 160:704-708.
15. Marmion B.P., Ormsbee R.A., Kyrkou M., Wright J., Worswick D., Cameron S., et al. Vaccine prophylaxis of abattoir-associated Q fever. Lancet 1984, 2:1411-1414.
16. Marmion B.P., Ormsbee R.A., Kyrkou M., Wright J., Worswick D.A., Izzo A.A., et al. Vaccine prophylaxis of abattoir-associated Q fever: eight years' experience in Australian abattoirs. Epidemiol Infect 1990, 104:275-287.
17. Milazzo A., Featherstone K.B., Hall R.G. Q fever vaccine uptake in South Australian meat processors prior to the introduction of the national Q fever management program. CDI 2005, 29:400-406.
18. Gefenaite G., Munster J.M., van Houdt R., Hak E. Effectiveness of the Q fever vaccine: a meta-analysis. Vaccine 2011, 29:395-398.
19. Holmes B.J. Communicating about emerging infectious disease: the importance of research. Health Risk Soc 2008, 10:349-360.
20. Vaughan E., Tinker T. Effective risk communication about pandemic influenza for vulnerable populations. Am J Public Health 2009, 99:S324-S332.
21. Gidding H.F., Wallace C., Lawrence G.L., McIntyre P.B. Australia's national Q fever vaccination program. Vaccine 2009, 27(14):2037-2041.
22. Breteler J.K., Oudhoff J.P., Munster J.M., Aarnoudse J.G., van Steenbergen J.E., Beaujean D.J.M.A. Risks, trust and knowledge: determinants of pregnant women's decision regarding participation in a future Q fever screening and treatment program during a large epidemic in The Netherlands. Prenat Diagn 2011, 10.1002/pd.2772.
23. Central Committee on Research involving Human Subjects. Manual for the review of medical research involving human subjects. Available from: . http://www.ccmo-online.nl/.
24. Bults M., Beaujean D.J.M.A., Richardus J.H., van Steenbergen J.E., Voeten H.A.C.M. Pandemic influenza A (H1N1) vaccination in the Netherlands: parental reasoning underlying child vaccination choices. Vaccine 2011, 29:6226-6235.
25. Brug J., Aro A.R., Oenema A., de Zwart O., Richardus J.H., Bischop G.D. SARS risk perception, knowledge, precautions, and information sources, the Netherlands. Emerg Infect Dis 2004, 10:1486-1489.
26. de Zwart O., Veldhuijzen I.K., Elam G., Aro A.R., Abraham T., Bishop G.D., et al. Avian influenza risk perception, Europe and Asia. Emerg Infect Dis 2007, 13:290-293.
27. Norman P., Boer H., Seydel E.R. Protection motivation theory. Predicting health behaviour 2005, 81-126. Open University Press, Berkshire, UK. M. Conner, P. Norman (Eds.).
28. Champion V.L., Skinner C.S. The health belief model. Health Behaviour and Health Education; Theory, Research, and Practice 2008, 45-65. Jossey Bass, San Francisco, CA. K. Glanz, B.K. Rimer, K. Viswanath (Eds.).
29. Zimmerman R.K., Nowalk M.P., Bardella I.J., Fine M.J., Janosky J.E., Santibanez T.A., et al. Physician and practice factors related to influenza vaccination among the elderly. Am J Prev Med 2004, 26:1-10.
30. Armstrong K., Berlin M., Schwartz J.S., Propert K., Ubel P.A. Barriers to influenza immunization in a low-income urban population. Am J Prev Med 2001, 20:21-25.
31. Mangtani P., Breeze E., Stirling S., Hanciles S., Kovats S., Fletcher A. Cross-sectional survey of older peoples' views related to influenza vaccine uptake. BMC Public Health 2006, 6:249.
32. van Essen G.A., Kuyvenhoven M.M., de Melker R.A. Why do healthy elderly people fail to comply with influenza vaccination. Age Ageing 1997, 26:275-279.
33. Fiebach N.H., Viscoli C.M. Patient acceptance of influenza vaccination. Am J Med 1991, 91:393-400.
34. Zimmerman R.K., Santibanez T.A., Janosky J.E., Fine M.J., Raymund M., Wilson S.A., et al. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and veterans affairs practices. Am J Med 2003, 114:31-38.
35. Burns V.E., Ring C., Carroll D. Factors influencing influenza vaccination uptake in an elderly, community-based sample. Vaccine 2005, 23:3604-3608.
36. Egede L.E., Zheng D. Racial/ethnic differences in influenza vaccination coverage in high-risk adults. Am J Public Health 2003, 93:2074-2078.
37. Kroneman M., Paget W.J., van Essen G.A. Influenza vaccination in Europe: an inventory of strategies to reach target populations and optimise vaccination uptake. Eurosurveill 2003, 8:130-138.